//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
@cancerassassin1.bsky.social and I break down the implications of the recent RASolute 302 phase 3 clinical trial, and the impact it will have on the field: ascopost.com/issues/june-... We have more publications coming on the future of KRAS! #ASCOPost #ASCO2026 #daraxonrasib #OncSky
11d
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated...
ascopost.com
Daraxonrasib in <em>KRAS</em>-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Ajay Prakash, MD, PhD